Phase III VICTORIA study of BAY 1021189 shows reduced risk of hospitalisation or death in heart failure.- Merck Inc + Bayer Healthcare
Related news and insights
Cytokinetics, Incorporated announced that the FDA issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for the treatment of heart failure with reduced ejection fraction (HFrEF)
AstraZeneca and Ono Pharmaceutical have secured a label update from Japanese regulators for their SGLT2 inhibitor Forxiga (dapagliflozin), which allows the drug’s use for chronic heart failure, irrespective of left ventricular ejection fraction (LVEF)
Cytokinetics, Incorporated announced that the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 8 to 3 that the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of heart failure with reduced ejection fraction (HFrEF).